JP2016518379A5 - - Google Patents

Download PDF

Info

Publication number
JP2016518379A5
JP2016518379A5 JP2016509434A JP2016509434A JP2016518379A5 JP 2016518379 A5 JP2016518379 A5 JP 2016518379A5 JP 2016509434 A JP2016509434 A JP 2016509434A JP 2016509434 A JP2016509434 A JP 2016509434A JP 2016518379 A5 JP2016518379 A5 JP 2016518379A5
Authority
JP
Japan
Prior art keywords
agent
composition according
sulfolobus
variant
fold protein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2016509434A
Other languages
English (en)
Other versions
JP2016518379A (ja
Filing date
Publication date
Priority claimed from FR1353662A external-priority patent/FR3004650B1/fr
Application filed filed Critical
Publication of JP2016518379A publication Critical patent/JP2016518379A/ja
Publication of JP2016518379A5 publication Critical patent/JP2016518379A5/ja
Pending legal-status Critical Current

Links

Claims (10)

  1. 野生型OBフォールドタンパク質のその天然リガンドへの結合界面に5から32個の変異残基を有する野生型OBフォールドタンパク質の変異体を含む、局所用組成物。
  2. 前記野生型OBフォールドタンパク質が、スルホロブス・アシドカルダリウス(Sulfolobus acidocaldarius)由来のSac7dまたはSac7e、スルホロブス・ソルファタリカス(Sulfolobus solfataricus)由来のSso7d、スルホロブス・トコダイイ(Sulfolobus tokodaii)由来のDBP 7、スルホロブス・シバタエ(Sulfolobus shibatae)由来のSsh7b、スルホロブス・シバタエ由来のSsh7a、およびスルホロブス・ソルファタリカス由来のp7ssから選択されることを特徴とする、請求項1記載の組成物。
  3. 10 mg/mlから600 mg/mlの前記変異体を含有することを特徴とする、請求項1および2のいずれか一項記載の組成物。
  4. 前記変異体が、抗原、抗体、細胞タンパク質、循環タンパク質、ペプチド、薬剤の活性成分、核酸、および特にインターロイキン、サイトカイン、サイトカインまたはインターロイキンの受容体、癌遺伝子によりコードされるタンパク質、微生物の表面タンパク質、ならびに微生物リポ多糖から選択される対象の標的に結合することを特徴とする、請求項1から3のいずれか一項記載の組成物。
  5. 皮膚に適用することが意図されていることを特徴とする、請求項1から4のいずれか一項記載の組成物。
  6. 眼レベルで適用することが意図されていることを特徴とする、請求項1から4のいずれか一項記載の組成物。
  7. 水性、油性もしくは水性-アルコール性溶液、エマルジョン、マイクロエマルジョン、水性ゲル、無水ゲル、美容液、小胞分散系、ローション、ゲル、クリーム、泡、エアロゾルまたはスプレーの形態にあることを特徴とする、請求項1から6のいずれか一項記載の組成物。
  8. 抗菌剤、抗寄生虫剤、抗真菌剤、抗炎症剤、鎮痒剤、麻酔剤、抗ウイルス剤、角質溶解剤、フリーラジカルスカベンジャー、抗脂漏剤、フケ防止剤、および抗ニキビ剤、ならびに皮膚の分化および/または増殖および/または色素沈着を調節するための作用物質から選択される少なくとも1つの作用物質も含有することを特徴とする、請求項1から7のいずれか一項記載の組成物。
  9. 皮膚または眼の障害または疾患の処置における使用のための、請求項1から8のいずれか一項記載の局所用組成物。
  10. 野生型OBフォールドタンパク質のその天然リガンドへの結合界面に5から32個の変異残基を有する野生型OBフォールドタンパク質の変異体を薬学的にまたは化粧用に許容される担体と混合する段階を含む、請求項1から9のいずれか一項記載の局所用組成物を調製するための方法。
JP2016509434A 2013-04-22 2014-04-22 Obフォールド変異体を含む局所用組成物 Pending JP2016518379A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR1353662A FR3004650B1 (fr) 2013-04-22 2013-04-22 Composition topique comprenant un variant d'une protéine sauvage à pli-OB, ainsi que son procédé de préparation
FR13/53662 2013-04-22
PCT/EP2014/058139 WO2014173899A1 (fr) 2013-04-22 2014-04-22 Compositions topiques comprenant des variantes de pli-ob

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2019022358A Division JP2019112410A (ja) 2013-04-22 2019-02-12 Obフォールド変異体を含む局所用組成物

Publications (2)

Publication Number Publication Date
JP2016518379A JP2016518379A (ja) 2016-06-23
JP2016518379A5 true JP2016518379A5 (ja) 2017-06-15

Family

ID=48795734

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2016509434A Pending JP2016518379A (ja) 2013-04-22 2014-04-22 Obフォールド変異体を含む局所用組成物
JP2019022358A Pending JP2019112410A (ja) 2013-04-22 2019-02-12 Obフォールド変異体を含む局所用組成物

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2019022358A Pending JP2019112410A (ja) 2013-04-22 2019-02-12 Obフォールド変異体を含む局所用組成物

Country Status (7)

Country Link
US (2) US10548945B2 (ja)
EP (1) EP2988766B1 (ja)
JP (2) JP2016518379A (ja)
CN (2) CN105338995B (ja)
ES (1) ES2637421T3 (ja)
FR (1) FR3004650B1 (ja)
WO (1) WO2014173899A1 (ja)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR3004650B1 (fr) * 2013-04-22 2015-05-29 Affilogic Composition topique comprenant un variant d'une protéine sauvage à pli-OB, ainsi que son procédé de préparation
FR3027521B1 (fr) 2014-10-24 2016-12-16 Affilogic Compositions pour administration par voie orale
EP3483180A1 (en) * 2017-11-14 2019-05-15 Affilogic Multi specific molecules
EP3632924A1 (en) 2018-10-07 2020-04-08 Affilogic Binders for inhibiting formation of multimeric proteins
US11597751B2 (en) 2019-05-16 2023-03-07 Massachusetts Institute Of Technology Glycan-binding proteins and related compositions and methods
EP3878858A1 (en) 2020-03-11 2021-09-15 Affilogic Variants of sac7d and their use in cancer therapy
EP4043481A1 (en) 2021-02-15 2022-08-17 Affilogic Compounds and methods for extending half life of biomolecules
EP4059949A1 (en) 2021-03-18 2022-09-21 Affilogic Anti-factor c3 sac7d variants and their medical use for treating complement-mediated disorders
EP4308590A1 (en) 2021-03-18 2024-01-24 Affilogic Anti-factor c3 sac7d variants and their medical use for treating complement-mediated disorders
CN117106745A (zh) * 2022-06-01 2023-11-24 北京擎科生物科技股份有限公司 逆转录突变体及其应用

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030228616A1 (en) * 1999-10-29 2003-12-11 Stratagene DNA polymerase mutants with reverse transcriptase activity
CA2653752A1 (en) * 2006-05-26 2007-12-06 Vickery Laurence Arcus Ob fold domains
ATE542830T1 (de) * 2006-12-04 2012-02-15 Pasteur Institut Als gerüst verwendeter ob-fold zur entwicklung neuer spezifischer bindemittel
EP2358746B1 (en) * 2008-11-03 2020-09-16 Molecular Partners AG Binding proteins inhibiting the vegf-a receptor interaction
US20110098216A1 (en) * 2009-10-22 2011-04-28 Regen Therapeutics Plc Therapeutic uses of colostrinin
EP2469278A1 (en) * 2010-12-21 2012-06-27 Institut Pasteur Reagentless fluorescent biosensors from nanofitins, rational design methods to create reagentless fluorescent biosensors and methods of their use
FR2974816A1 (fr) * 2011-05-04 2012-11-09 Centre Nat Rech Scient Methode de generation de proteines
FR3004650B1 (fr) * 2013-04-22 2015-05-29 Affilogic Composition topique comprenant un variant d'une protéine sauvage à pli-OB, ainsi que son procédé de préparation
FR3027521B1 (fr) * 2014-10-24 2016-12-16 Affilogic Compositions pour administration par voie orale
PL412787A1 (pl) * 2015-06-22 2017-01-02 Magdalena Król Oparty na makrofagach celowany system dostarczania związków związanych z ferrytyną
WO2018048941A2 (en) * 2016-09-08 2018-03-15 The Board Of Trustees Of The Leland Stanford Junior University Use of high affinity monoclonal antibody product binders to increase the duration of action of therapeutic monoclonal antibody products in a biologic tissue
EP3483180A1 (en) * 2017-11-14 2019-05-15 Affilogic Multi specific molecules
EP3632924A1 (en) * 2018-10-07 2020-04-08 Affilogic Binders for inhibiting formation of multimeric proteins
EP3878858A1 (en) * 2020-03-11 2021-09-15 Affilogic Variants of sac7d and their use in cancer therapy
EP4059949A1 (en) * 2021-03-18 2022-09-21 Affilogic Anti-factor c3 sac7d variants and their medical use for treating complement-mediated disorders

Similar Documents

Publication Publication Date Title
JP2016518379A5 (ja)
Chaulagain et al. Passive delivery of protein drugs through transdermal route
HRP20190799T1 (hr) Imunocitokini na bazi il-15 i sushi domene il-15r alfa
EP4299137A3 (en) Extracellular vesicle comprising a fusion protein having fc binding capacity
WO2019126762A3 (en) Cas12a systems, methods, and compositions for targeted rna base editing
WO2020077276A3 (en) Pd-1 targeted il-15/il-15ralpha fc fusion proteins and uses in combination therapies thereof
MX2018010824A (es) Proteinas de union inducibles y metodos de uso.
JP2015530358A5 (ja)
BR112015022210A2 (pt) formulações farmacêuticas aquosas estáveis, seu uso, artigo de manufatura, métodos de redução da agregação de um anticorpo monoclonal terapêutico e método de produção de uma formulação farmacêutica.
CN105884888B (zh) 一种基于金纳米粒子的人工抗体构建方法
WO2019241893A3 (en) Anti-her3 antibody and uses thereof
WO2017066132A3 (en) Synthetic antibody mimic peptides
US20160143990A1 (en) Topical Compositions Comprising OB-Fold Variants
CN105980447A (zh) 二氧化硅囊泡的合成方法及其用途
WO2007119011A9 (fr) Proteines de fusion proteine n d'un virus de la famille des paramyxoviridae-proteine d'interet
HRP20161096T1 (hr) Antigenski vežući proteini specifični za komponentu p serumskog amiloida
WO2019180201A3 (en) Antagonistic pd-1, pd-l1 and lag-3 binding proteins
BR112019028070A2 (pt) peptídeos e combinações de peptídeos para uso em imunoterapia contra câncer de pulmão, incluindo cpcnp, cppc e outros cânceres
WO2016063026A3 (en) Selective nav protein binders
RU2019113989A (ru) Лекарственное средство
BR112019005001A2 (pt) proteína de ligação ao antígeno, proteína de fusão, ácido nucleico, vetor recombinante, célula hospedeira recombinante, composição farmacêutica, uso médico da proteína de ligação ao antígeno e método de inibição do crescimento tumoral
WO2014144768A3 (en) Bh4 stabilized peptides and uses thereof
BR112022014574A2 (pt) Proteína heterodimérica, anticorpo ativável, um ou mais ácidos nucleicos, vetor, célula hospedeira, composição farmacêutica e métodos para preparar uma proteína heterodimérica ou um anticorpo ativável e para tratar uma doença
WO2018020324A3 (en) Virus-like particles with high-density coating for inducing the expression of antibodies
EA202190572A1 (ru) Иммунотерапия раковых заболеваний рестриктированными по a*01 пептидами и комбинациями пептидов и относящиеся к ней способы